NCT01718964

Brief Summary

To investigate the effects of cortisol on heroin craving and stress reaction in heroin addicted subjects Randomized, double-blind, placebo-controlled, cross-over, single administration of study medication Study hypothesis:Cortisol has an inhibiting effect on heroin craving and stress reactivity in opioid dependent subjects.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at P25-P50 for phase_2

Timeline
Completed

Started Nov 2012

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 23, 2012

Completed
9 days until next milestone

First Posted

Study publicly available on registry

November 1, 2012

Completed
Same day until next milestone

Study Start

First participant enrolled

November 1, 2012

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2013

Completed
Last Updated

October 30, 2013

Status Verified

October 1, 2013

Enrollment Period

8 months

First QC Date

October 23, 2012

Last Update Submit

October 29, 2013

Conditions

Outcome Measures

Primary Outcomes (1)

  • Heroin craving

    outcome measures will be taken during the participants 2 test visit days. Each participant will stay for approx. 3 hours.

    baseline, change from baseline during and after presentation of drug stimuli

Secondary Outcomes (1)

  • Anxiety

    baseline, change from baseline during and after presentation of drug stimuli

Other Outcomes (2)

  • Symptoms of withdrawal

    baseline, change from baseline during and after presentation of drug stimuli

  • saliva cortisol level

    baseline, change from baseline during and after presentation of drug stimuli

Study Arms (2)

A

OTHER

Cortisol 20 mg /Placebo Mannitol

Drug: Cortisol 20 mgDrug: Mannitol

B

OTHER

Placebo Mannitol/Cortisol 20mg

Drug: Cortisol 20 mgDrug: Mannitol

Interventions

Mannitol used as placebo

AB

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age ≥ 18
  • Opioid dependency
  • Participant in the Janus heroin programme of the UPK Basel
  • Able to control parallel consumption of other drugs
  • Stable i.v. substitution for at least 3 months

You may not qualify if:

  • co-morbid psychiatric disturbances
  • Current medical conditions excluding participation
  • Recent history of systemic or topic glucocorticoid therapy
  • known hypersensitivity to the IMP under investigation (cor-tisol)
  • pregnancy, breast-feeding
  • inability to read and understand the participant's information

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Psychiatric Hospital

Basel, 4012, Switzerland

Location

Related Publications (1)

  • Walter M, Bentz D, Schicktanz N, Milnik A, Aerni A, Gerhards C, Schwegler K, Vogel M, Blum J, Schmid O, Roozendaal B, Lang UE, Borgwardt S, de Quervain D. Effects of cortisol administration on craving in heroin addicts. Transl Psychiatry. 2015 Jul 28;5(7):e610. doi: 10.1038/tp.2015.101.

MeSH Terms

Conditions

Opioid-Related Disorders

Interventions

HydrocortisoneMannitol

Condition Hierarchy (Ancestors)

Narcotic-Related DisordersSubstance-Related DisordersChemically-Induced DisordersMental Disorders

Intervention Hierarchy (Ancestors)

PregnenedionesPregnenesPregnanesSteroidsFused-Ring CompoundsPolycyclic Compounds11-HydroxycorticosteroidsHydroxycorticosteroidsAdrenal Cortex HormonesHormonesHormones, Hormone Substitutes, and Hormone Antagonists17-HydroxycorticosteroidsSugar AlcoholsAlcoholsOrganic ChemicalsCarbohydrates

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Professor MD

Study Record Dates

First Submitted

October 23, 2012

First Posted

November 1, 2012

Study Start

November 1, 2012

Primary Completion

July 1, 2013

Study Completion

July 1, 2013

Last Updated

October 30, 2013

Record last verified: 2013-10

Locations